Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442689 · ClinicalTrials.gov registry record · NA
Metabolic Syndrome in PCOS: Precursors and Interventions
A NA study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT00442689: Completed NA study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by Northwestern University.
NCT00442689 is a NA study of Metabolic Syndrome and Polycystic Ovary Syndrome that has completed, run by Northwestern University. The registered enrollment target is 97 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00442689, a NA study of Metabolic Syndrome and Polycystic Ovary Syndrome, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement in metabolic markers in PCOS women and would reduce their long term metabolic risk.
Primary Outcome
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level)
Conditions Studied
Interventions
- OTHER placebo
- DRUG flutamide
- DRUG ethinyl estradiol 35 mcg and drospirenone 3 mg
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-11 |
| Phase | NA |
What the finished NCT00442689 record still lists
NCT00442689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00442689 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00442689 about?
NCT00442689 is a clinical study titled "Metabolic Syndrome in PCOS: Precursors and Interventions". The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement ...
What is the current status of trial NCT00442689?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2006-07. Estimated completion is 2012-11.
What conditions does trial NCT00442689 study?
This clinical trial studies the following conditions: Metabolic Syndrome, Polycystic Ovary Syndrome.
What interventions are being tested in trial NCT00442689?
The interventions under investigation include: placebo (OTHER), flutamide (DRUG), ethinyl estradiol 35 mcg and drospirenone 3 mg (DRUG).
Who is sponsoring clinical trial NCT00442689?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00442689 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00442689's enrollment target sits among peer trials
97 34th of 102 higher than 69 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Animal and Plant Proteins and Glucose Metabolism
RECRUITING · NA
-
VR Stimulation of Exercise Response in Sedentary Humans
RECRUITING · NA
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia